FDA approves Imbruvica for pediatric cGVHD

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

FDA approved Imbruvica (ibrutinib) for pediatric patients 1 year of age or older with chronic graft versus host disease after failure of 1 or more lines of systemic therapy. Formulations include capsules, tablets, and oral suspension.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

The largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure found that carvedilol, a blood vessel relaxing medication, is safe for childhood cancer survivors and may improve important markers of heart injury sustained as a result of chemotherapy exposure.

Login